8.73

3.56% 0.30

After Hours: 8.76 0.03 +0.34%

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $8.73, with a volume of 2.23M. It is up +3.56% in the last 24 hours and up +30.49% over the past month. Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Previous Close:

$8.43

Open:

$8.43

24h Volume:

2.23M

Relative Volume:

0.83

Market Cap:

$628.03M

Revenue:

$409.00K

Net Income/Loss:

$-101.35M

P/E Ratio:

-5.3558

EPS:

-1.63

Net Cash Flow:

$-71.49M

1W Performance:

+8.45%

1M Performance:

+30.49%

6M Performance:

+19.10%

1Y Performance:

+185.29%

1-Day Range:

$8.23

$9.00

1-Week Range:

$7.91

$9.23

52-Week Range:

$2.89

$14.84

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	8.73	628.03M	409.00K	-101.35M	-71.49M	-1.63
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

Nov 27, 2024

How To Trade (ALT) - Stock Traders Daily

Nov 27, 2024

Nov 26, 2024

Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times

Nov 26, 2024

Altimmune to Present at Evercore and Piper Sandler Healthcare Conferences in December | ALT Stock News - StockTitan

Nov 26, 2024

Nov 22, 2024

Altimmune (ALT) Price Target Increased by 16.42% to 22.73 - MSN

Nov 22, 2024

Nov 21, 2024

Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? - Insider Monkey

Nov 21, 2024

11 Reddit Stocks with Biggest Upside Potential - Insider Monkey

Nov 21, 2024

Nov 18, 2024

FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat

Nov 18, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024

Nov 16, 2024

(ALT) Trading Report - Stock Traders Daily

Nov 16, 2024

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com

Nov 16, 2024

Nov 15, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times

Nov 15, 2024

What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat

Nov 15, 2024

Nov 14, 2024

AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com

Nov 14, 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha

Nov 13, 2024

Altimmune Unusual Options Activity For November 13 - Benzinga

Nov 13, 2024

Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha

Nov 13, 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks

Nov 13, 2024

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq

Nov 13, 2024

GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India

Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada

Nov 13, 2024